Berlin - Delayed Quote EUR

Collegium Pharmaceutical Inc (354.BE)

24.00

+0.60

+(2.56%)

As of 8:13:04 AM GMT+2. Market Open.

3 Healthcare Stocks That Concern Us

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.7%. This drawdown was worse than the S&P 500’s 5.2% decline.

StockStory yesterday

CORT

SEM

COLL
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmace

GlobeNewswire 5 days ago

COLL
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 6 days ago

COLL
2 Reasons to Watch COLL and 1 to Stay Cautious

Collegium Pharmaceutical’s stock price has taken a beating over the past six months, shedding 31.6% of its value and falling to $26.01 per share. This might have investors contemplating their next move.

StockStory 15 days ago

COLL
Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 30% ROE Better Than Average?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. 27 days ago

COLL
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q4.

StockStory 27 days ago

COLL

SUPN

ZTS
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpha

GlobeNewswire 28 days ago

COLL
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting

STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule I

GlobeNewswire last month

COLL
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Bo

GlobeNewswire last month

AVTX

COLL

BHVN
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX) and the rest of the branded pharmaceuticals stocks fared in Q4.

StockStory last month

SUPN

COLL

ZTS
Teva Pharmaceutical Stock Scores RS Rating Upgrade

Teva Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investor's Business Daily last month

COLL

ANIP

HLN
Collegium Announces Updates to its Board of Directors and Executive Leadership Team

– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Collegium Phar

GlobeNewswire last month

COLL
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, bein

GlobeNewswire last month

COLL
Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors

Even though Collegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) recent earnings release was robust, the market didn't seem...

Simply Wall St. last month

COLL
Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare ConferenceTuesday, March 11, 2025 Jefferies Biotech on the Beach SummitWednesday, March 12, 2025 Barclays 27th Annual Global Healthcare ConferenceThursday, March 13, 2025 About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified

GlobeNewswire last month

COLL
Collegium Pharmaceutical Full Year 2024 Earnings: In Line With Expectations

Collegium Pharmaceutical ( NASDAQ:COLL ) Full Year 2024 Results Key Financial Results Revenue: US$631.4m (up 11% from...

Simply Wall St. last month

COLL
Should You Be Adding Collegium Pharmaceutical (NASDAQ:COLL) To Your Watchlist Today?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Simply Wall St. last month

COLL
Is Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now?

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Collegium Pharmaceutical, Inc. (NASDAQ:COLL) stands against the other small cap pharma stocks. Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry Emily Field, Head of […]

Insider Monkey last month

COLL
Q4 2024 Collegium Pharmaceutical Inc Earnings Call

Q4 2024 Collegium Pharmaceutical Inc Earnings Call

Thomson Reuters StreetEvents last month

COLL
Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Collegium Pharmaceutical Inc (COLL) reports a 22% increase in Q4 net product revenues, driven by successful acquisitions and strategic growth initiatives.

GuruFocus.com last month

COLL

Performance Overview

Return	354.BE	S&P 500 (^GSPC)
YTD	-13.04%	-5.45%
1-Year	-29.41%	+10.43%
3-Year	+60.00%	+34.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Collegium Pharmaceutical Inc (354.BE)

3 Healthcare Stocks That Concern Us

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

2 Reasons to Watch COLL and 1 to Stay Cautious

Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 30% ROE Better Than Average?

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

Teva Pharmaceutical Stock Scores RS Rating Upgrade

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical Full Year 2024 Earnings: In Line With Expectations

Should You Be Adding Collegium Pharmaceutical (NASDAQ:COLL) To Your Watchlist Today?

Is Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now?

Q4 2024 Collegium Pharmaceutical Inc Earnings Call

Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Performance Overview